Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs VyrarX

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and VyrarX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 250 · Grade C

VyrarX

Visit VyrarX Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 66 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make VyrarX a bad call — it's best for readers seeking online clinician messaging who will obtain the medication, pharmacy and payment details before choosing a plan. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
75
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
89
Track Record
88
73
CoreAge RxBrief Score 94 · 66VyrarX

Price, coverage & the tracker

CoreAge RxVyrarX
Brief Score94/100 (A)66/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm prescription and full charge

Semaglutide advertised from $179/month; exact formulation, supplied quantity and fee breakdown unconfirmed.

Terms exclude California, South Carolina and New Jersey; individual eligibility applies.

Full price details

Semaglutide offered; formulation and complete selected-plan quote unknown; homepage advertises weekly injections from $179/month without supplied quantity or full fee breakdown

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm prescription and full charge

Tirzepatide advertised from $329/month; exact formulation, supplied quantity and fee breakdown unconfirmed.

Unused subscription periods generally are not refundable; confirm the prescription-order status.

Full price details

Tirzepatide offered; formulation and complete selected-plan quote unknown; homepage advertises from $329/month without supplied quantity or full fee breakdown

CoverageUS only; restrictions by state, confirmed at intakeTerms exclude California, South Carolina and New Jersey; individual clinical eligibility still applies
Brand-name accessNot confirmedA current branded GLP-1 offer was not established; the exact prescription remains unconfirmed.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

VyrarX: Semaglutide from $179/month and tirzepatide from $329/month are starting advertisements; confirm the full selected supply, formulation and charge.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.